Celldex Therapeutics, Inc (CLDX) Financials
Key financial figures for Celldex Therapeutics, Inc (Q2 2026).
Celldex Therapeutics reported revenue of $22.0 thousand for Q2 FY2026, down 97.0% from the same period a year earlier. The company posted a net loss of $73.5 million, or -$0.94 per share. Operating margin came to -366468.18%, against -8747.53% a year earlier. Free cash flow for the period was -$60.6 million. Across the last 5 reported quarters, quarterly revenue has moved from $730.0 thousand in Q2 FY2025 to $22.0 thousand in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Celldex Therapeutics are on the SentiSense financials page.
- Revenue
- $22K
- Net Income
- -$74M
- EPS
- $-0.94
- Total Assets
- $782M
- Operating Cash Flow
- -$57M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $22K | -$74M | -$0.94 | -366468.18% | -$61M |
| Q1 FY2026 | $15K | -$79M | -$1.18 | -562900% | -$67M |
| Q4 FY2025 | $75K | -$81M | -$1.23 | -116249.33% | -$65M |
| Q3 FY2025 | $0 | -$67M | -$1.01 | -$49M | |
| Q2 FY2025 | $730K | -$57M | -$0.85 | -8747.53% | -$45M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2M | -$259M | -$3.90 | -19160% | -$214M |
| FY2024 | $7M | -$158M | -$2.45 | -2778.89% | -$160M |
| FY2023 | $7M | -$141M | -$2.92 | -2245.27% | -$109M |
Frequently asked questions
What was Celldex Therapeutics's revenue last quarter?
Celldex Therapeutics reported revenue of $22.0 thousand for Q2 FY2026, down 97.0% from the same period a year earlier.
Is Celldex Therapeutics profitable?
Not in its most recent reported period. Celldex Therapeutics reported a net loss of $73.5 million for Q2 FY2026, a net margin of -334104.55% on revenue.
How has Celldex Therapeutics's margin trended?
Operating margin was -366468.18% in Q2 FY2026, compared with -8747.53% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Celldex Therapeutics generate?
Celldex Therapeutics generated free cash flow of -$60.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Celldex Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.